Uncategorized

Novo and Lilly battle over GLP-1 claims only a head-to-head trial can answer

Published

on

A day after Eli Lilly gained FDA approval for its obesity pill Foundayo, Novo Nordisk is fighting back with an analysis that it says shows the superiority of its own oral drug.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version